As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.

Adults with serious mental illness receive GLP-1 prescriptions at rates similar to or higher than their peers, though schizophrenia continued to lag.

A study found that age and physical comorbidities—not psychiatric diagnosis—were associated with nonpsychotropic polypharmacy.

The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.

Madeline Sutton, MD, MPH, FACOG, joins to discuss risks of HPV infection among women and how pharmacists can improve outcomes in this area.

In part 2, Vanessa Slowey explains the pharmacy industry’s need for due diligence as technology reinforces patient convenience in the 21st century.

As pharmacists vocalize their willingness to fill in health care gaps, the integration of public health and emerging pharmacy professionals could be profound.

The expert explains 2025-1016 flu, COVID-19, and RSV vaccine updates from AAP, ACOG, AAFP, and IDSA, and what changing schedules mean for pharmacists.